Page 6 - Virtual Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

uniQure Inc.: uniQure to Participate in Multiple Upcoming Industry Conferences in June ~ uniQure to host virtual Research & Development Day on June 22, 2021 ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2021(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: Jefferies Virtual Healthcare Conference, June 1 - 4, 2021 Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the d...

~ uniQure to host virtual Research & Development Day on June 22, 2021 ~LEXINGTON, Mass. and AMSTERDAM, June 02, 2021(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for

April 14, 2021 healthcare Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer. ...

 E-Mail HOUSTON and Ingelheim, Germany ? The University of Texas MD Anderson Cancer Center and Boehringer Ingelheim today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim's KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer. The collaboration, launched in 2019, has successfully combined MD Anderson's innovative clinical research infrastructure and the patient...

(0) Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center (VRDC) The continued collaboration will explore lung cancer targeting KRAS and TRAILR2 molecules from Boehringer Ingelheim's growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancer Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to expl...